medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2006, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2006; 4 (4)

Mycosis Fungoides: its biology and therapeutic

González-Ramírez RA, Ocampo-Candiani J, Méndez-Olvera N, Gómez-Flores M

Language: Spanish
References: 32
Page: 278-287
PDF size: 443.40 Kb.


ABSTRACT

Mycosis fungoides, the most frequent form of cutaneous T cell lymphomas (CTCL) is initially indolent but can spread far from skin. It usually affects men, predominantly afroamericans. Several etiopathogenic factors have been linked to, such as viral infections, chemicals, sun exposure, smoking, etcetera. T cells and some adhesion molecules have a primary role in the development of this disease, which is considered inicially as a chronic inflammatory disease with potential malignization. It has 3 clinical stages: patchy, plaques and tumour. Also Sézary syndrome which is characterized for the presence of malignant cells in peripheral blood. Therapy depends on clinical stage, this therapeutic array has increased recently.


REFERENCES

  1. Epstein EH, Zackheim HS, McNutt NS. “Mycosis fungoides and variants”. En: Demis DJ. Clinical Dermatology. 1th Edition. 17 reimp. J B Lippincot Company. Vol 4 Chapter 20-11, 1990

  2. Sézary A, Bouvrain Y. Erythrodermie avec presence de cellules montrueuses dans le derme et dans le lang circulant. Bull Soc Fr Dermatol Syphiligr 1938; 45: 254-260

  3. Wilson LD, Kacinski BM, Edelson RL, Heald PW. “Cutaneous TCell Lymphomas”. En: DeVita Jr VT, Hellman S, Rosemberg SA. Cancer: Principles and Practice of Oncology. 5th Edition. Lippincot-Raven Contributors. Chapter 44.4; 1997: 2220-2230

  4. Whittemore AS, Holly EA, Lee IM, et al. Mycosis Fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 1989; 81: 1560-1567

  5. Morales-Suárez-Varela MM, Olsen J, Johansen P, et al. Occupational risk factors for mycosis fungoides: A European multicenter case-control study. J Occup Environ Med 2004; 46: 205-211

  6. Góngora Biachi RA, González-Martínez P, Puerto-Manzano F, Yamaguchi K, Nishimura Y, Takatsuki K. Micosis fungoide asociada al virus linfotrópico de células T humanas en Yucatán. Rev Invest Clin 1991; 43: 111

  7. Pancake BA, Zucker-Franklin D, Coutavas EE. The Cutaneous T Cell Lymphoma, Mycosis Fungoides, Is a Human T Cell Lymphotrophic Virusassociated Disease: a study of 5 patients. J Clin Invest 1995; 95: 547-554

  8. Robert C. Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. NEJM 1999; 341 (24): 1827-1828

  9. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. NEJM 2004; 350 (19): 1978-1988

  10. Rossete C. Karin M. Ultraviolet light and osmotic stress: activation of the INK cascade through multiple growth factor and cytokine receptors. Science 1996; 274: 1194-1197

  11. Suchin KR, Cassin M, Gottleib SL et al. Increased interleukin 5 production in eosinophilic Sézary syndrome: Regulation by interferon alfa and interleukin

  12. J Am Acad Dermatol 2001; 44: 28-32 12. Kim EJ, Hess S, Richardson SK. Inmunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115 (4): 798-812

  13. EntrezPubmed: http://www.ncbi.nlm.nih.gov/nationalcenterforbiotechnologyinformation. com.

  14. Scarisbrick JJ, Mitchell TJ, Calonje E et al. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003; 121: 894-901

  15. Navas IC, Ortiz-Romero PL, Villuendas R y cols. P16INK4a gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 2000; 156: 1565-1572

  16. Van Doorn R, Zoutman WH, Dijkman R et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005; 23: 3886-3896

  17. Ni X, Hazarika P, Zhang C et al. Fas ligand expresión by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682-2692

  18. Strutton G. “Cutaneous infiltrates-lymphomatous and leukemic”. En: Weedon D. Skin Pathology. 2a ed. Churchill Livingstone 2002. Chapter 41: 1104-1111

  19. Sokolowska-Wojdylo M, Wenzel J, Gaffal E. Circulating clonal CLA4+ T cells in Sézary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005; 152: 258-264

  20. 20.Bunn PA, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725-728

  21. Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 45: 700-706

  22. Vonderheid EC, Bernengo MG, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-106

  23. Massone C, Kodama K, Kerl H, Cerroni L. Histopathologic features of early (patch) lesions of Mycosis Fungoides: a morphology study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005; 29 (4): 550-560

  24. Breneman DL, Raju US, Breneman JC et al. Lymph node grading for staging of mycosis fungoides may benefit from examination of multiple excised lymph nodes. J Am Acad Dermatol 2003; 48 (5): 702-706

  25. Lee BN, Duvic M, Tang CHK et al. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999; 6 (1): 79-84

  26. 26.Bergman R, Faclieru D, Sahar D et al. Immunophenotyping and T-cell receptor Á gene rearrangement analysis as an adjunt to the histopathologic diagnosis of mycosis fungoides. J Am Acad Dermatol 1998; 39: 554-559

  27. Dearden CE, Foss FM. Peripheral T-cell lymphomas: diagnosis and management. Hematol Oncol Clin N Am 2003; 17: 1351-1366

  28. Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 2005; 12: 273-278 29.Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematol Oncol Clin N Am 2003; 17: 1459-1466

  29. 30.Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin N Am 2003; 17: 1475-1483

  30. Herbert KE, Spencer A, Grigg A et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplantation 2004; 34: 521-525

  31. Brightman L, Demierre MF. Thalidomide in mycosis fungoides. Letters. J Am Acad Dermatol 2005; 52 (6): 1100-1101

  32. Klemke CD, Mansmann U, Poenitz N et al. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005; 153: 118-124 Volumen




2020     |     www.medigraphic.com